skip to main content

Levetiracetam Preferred Anticonvulsant CKD — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateChronic Kidney DiseaseLevetiracetam Preferred Anticonvulsant CKDESENeph

A 35-year-old woman with CKD G3a and epilepsy on Levetiracetam asks about its safety in CKD. Why is Levetiracetam preferred over Carbamazepine or Phenytoin in CKD patients?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Levetiracetam has no hepatic CYP enzyme interactions

Levetiracetam is the preferred anticonvulsant in CKD/transplant patients because: (1) no CYP enzyme interactions – Carbamazepine/Phenytoin induce CYP3A4, dramatically reducing Tacrolimus/Ciclosporin levels in transplant patients; (2) predictable pharmacokinetics with renal dose adjustment (unlike Phenytoin's unpredictable protein binding in CKD); (3) does not induce vitamin D catabolism (enzyme-inducing anticonvulsants accelerate 25-OH vitamin D clearance, worsening CKD-MBD and osteoporosis); (4) no significant effect on bone metabolism. The main disadvantage is renal clearance requiring dose reduction in CKD and supplemental dosing post-dialysis.

Reference: https://guidelines.ukkidney.org